CRC Research Update — August 25, 2026
Today's colorectal cancer research highlights
decision-making
A collection of 70 issues
Liquid biopsy may redefine surgical decision-making in colorectal cancer
Skip to content
The CRC Digest
Liquid biopsy may redefine surgical decision-making in colorectal cancer
A scoping review found that liquid biopsy offers a dynamic measure of tumor biology that complements pathological staging and guides postoperative management beyond conventional anatomy-based risk stratification. (Updates in Surgery)
This content is informational only
Sports Team Branding on Mailed Screening Kits Tested as Engagement Strategy
Skip to content
The CRC Digest
▪ SCREENING
Sports Team Branding on Mailed Screening Kits Tested as Engagement Strategy
A randomized quality improvement study examined whether adding sports team branding and discount incentives to mailed colorectal cancer screening kits improved screening uptake. (Gastroenterology and Hepatology Advances)
This content is informational only
Synthetic Control Arms From Historical Trial Data May Help Design Future Metastatic CRC Trials
Skip to content
The CRC Digest
◆ TRIAL DATA
Synthetic Control Arms From Historical Trial Data May Help Design Future Metastatic CRC Trials
Researchers used the ARCAD database to construct external control arms from historical trial data for seven landmark metastatic colorectal cancer trials, evaluating whether this approach could complement traditional
What helps survivors use their care plans after treatment
Skip to content
The CRC Digest
♥ LIVING WITH CRC
What helps survivors use their care plans after treatment
Interviews with 30 breast and colorectal cancer survivors found that survivorship care plans were most helpful when survivors discussed them with their primary care providers and found the information reassuring and relevant
CRC Research Update — August 20, 2026
Today's colorectal cancer research highlights
CRC Research Update — August 18, 2026
Today's colorectal cancer research highlights
Toxicity Comparison Tool Helps Patients Choose Between Fruquintinib and Regorafenib
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Toxicity Comparison Tool Helps Patients Choose Between Fruquintinib and Regorafenib
Researchers developed a weighted toxicity score to help patients and clinicians compare side effects between two later-line treatment options, supporting more informed treatment decisions in metastatic colorectal cancer. (Clinical Colorectal Cancer)
CRC Research Update — August 17, 2026
Today's colorectal cancer research highlights
CRC Research Update — August 10, 2026
Today's colorectal cancer research highlights